Table 1.
Baseline characteristics of patients enrolled in the effective and placebo/ineffective treatment groups.
Figure 1.
Sensitivity to change of MRP8/14 serum levels compared to DAS28 and CRP serum level.
Standardized response mean (SRM) of the change in myeloid related protein 8/14 (MRP8/14), C-reactive protein (CRP) and disease activity score evaluated in 28 joints (DAS28-CRP) 4 weeks after treatment with infliximab (n = 34), adalimumab (n = 85), rituximab (n = 20) and treatment with placebo or ineffective therapy (n = 28). The solid line indicates the 0.2 SRM cut off point (low), the thick dotted line indicates the 0.5 SRM cut off point (moderate) and the thin dotted line indicates the 0.8 SRM cut off point (high).